These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24378455)

  • 41. Possible relationship between Al/ferritin complex and Alzheimer's disease.
    De Sole P; Rossi C; Chiarpotto M; Ciasca G; Bocca B; Alimonti A; Bizzarro A; Rossi C; Masullo C
    Clin Biochem; 2013 Jan; 46(1-2):89-93. PubMed ID: 23103708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.
    Platis O; Anagnostopoulos G; Farmaki K; Posantzis M; Gotsis E; Tolis G
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():279-81. PubMed ID: 16462711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute iron intoxication: change in urine color during chelation therapy with deferoxamine.
    Fernández S; Castro P; Nogué S; Nicolás JM
    Intensive Care Med; 2014 Jan; 40(1):104. PubMed ID: 24072332
    [No Abstract]   [Full Text] [Related]  

  • 46. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
    Mandel S; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration.
    Canteros-Picotto A; Fernández-Martín JL; Cannata-Andía JB
    Am J Kidney Dis; 2000 Nov; 36(5):969-75. PubMed ID: 11054353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum.
    Kruck TP; Cui JG; Percy ME; Lukiw WJ
    Cell Mol Neurobiol; 2004 Jun; 24(3):443-59. PubMed ID: 15206824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperpigmentation and secondary hemochromatosis: a novel treatment with extracorporeal chelation.
    Held JL; Yankiver B; Kohn SR
    J Am Acad Dermatol; 1993 Feb; 28(2 Pt 1):253-4. PubMed ID: 8432923
    [No Abstract]   [Full Text] [Related]  

  • 52. Nanoparticle and other metal chelation therapeutics in Alzheimer disease.
    Liu G; Garrett MR; Men P; Zhu X; Perry G; Smith MA
    Biochim Biophys Acta; 2005 Sep; 1741(3):246-52. PubMed ID: 16051470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Desferrioxamine for Alzheimer's disease.
    Lancet; 1991 Aug; 338(8762):324-6. PubMed ID: 1677151
    [No Abstract]   [Full Text] [Related]  

  • 54. Iron chelation and nanoparticle target delivery in the development of new multifunctional disease-modifying drugs for Alzheimer's disease.
    Liu G; Men P; Zhu X; Perry G
    Ther Deliv; 2012 May; 3(5):571-4. PubMed ID: 22834400
    [No Abstract]   [Full Text] [Related]  

  • 55. Determination of desferoxamine and a major metabolite by high-performance liquid chromatography. Application to the treatment of aluminium-related disorders.
    Kruck TP; Kalow W; McLachlan DR
    J Chromatogr; 1985 May; 341(1):123-30. PubMed ID: 4019677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ascorbic acid, iron overload, and desferrioxamine.
    Halliwell B
    Br Med J (Clin Res Ed); 1982 Jul; 285(6337):296. PubMed ID: 6807463
    [No Abstract]   [Full Text] [Related]  

  • 57. Neurochemical hypothesis: participation by aluminum in producing critical mass of colocalized errors in brain leads to neurological disease.
    Joshi JG
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1991; 100(1-2):103-5. PubMed ID: 1677837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chelation therapy. Unproved modality in the treatment of Alzheimer-type dementia.
    Cardelli MB; Russell M; Bagne CA; Pomara N
    J Am Geriatr Soc; 1985 Aug; 33(8):548-51. PubMed ID: 3926855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transferrin, cholesterol and aluminium in Alzheimer's disease.
    Corrigan FM; Crichton JS; Van Rhijn AG; Skinner ER; Ward NI
    Clin Chim Acta; 1992 Oct; 211(1-2):121-3. PubMed ID: 1468151
    [No Abstract]   [Full Text] [Related]  

  • 60. A first-principles study on potential chelation agents and indicators of Alzheimer's disease.
    Wang B; Luo X
    RSC Adv; 2020 Sep; 10(58):35574-35581. PubMed ID: 35515673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.